212 related articles for article (PubMed ID: 21478267)
1. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells.
Katiyar P; Aplin AE
Mol Cancer Res; 2011 May; 9(5):545-52. PubMed ID: 21478267
[TBL] [Abstract][Full Text] [Related]
2. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Abel EV; Aplin AE
Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
[TBL] [Abstract][Full Text] [Related]
3. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization.
Klein RM; Spofford LS; Abel EV; Ortiz A; Aplin AE
Mol Biol Cell; 2008 Feb; 19(2):498-508. PubMed ID: 18045987
[TBL] [Abstract][Full Text] [Related]
4. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
Han S; Ren Y; He W; Liu H; Zhi Z; Zhu X; Yang T; Rong Y; Ma B; Purwin TJ; Ouyang Z; Li C; Wang X; Wang X; Yang H; Zheng Y; Aplin AE; Liu J; Shao Y
Nat Commun; 2018 Jan; 9(1):28. PubMed ID: 29295999
[TBL] [Abstract][Full Text] [Related]
5. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Basile KJ; Abel EV; Aplin AE
Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
[TBL] [Abstract][Full Text] [Related]
6. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions.
Klein RM; Aplin AE
Cancer Res; 2009 Mar; 69(6):2224-33. PubMed ID: 19244113
[TBL] [Abstract][Full Text] [Related]
7. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.
Klein RM; Higgins PJ
Mol Cancer; 2011 Sep; 10():114. PubMed ID: 21917148
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Gassenmaier M; Rentschler M; Fehrenbacher B; Eigentler TK; Ikenberg K; Kosnopfel C; Sinnberg T; Niessner H; Bösmüller H; Wagner NB; Schaller M; Garbe C; Röcken M
Am J Pathol; 2020 Oct; 190(10):2155-2164. PubMed ID: 32679231
[TBL] [Abstract][Full Text] [Related]
9. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
10. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.
Weiss MB; Abel EV; Dadpey N; Aplin AE
Mol Cancer Res; 2014 Sep; 12(9):1314-23. PubMed ID: 25061102
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
Gaggioli C; Robert G; Bertolotto C; Bailet O; Abbe P; Spadafora A; Bahadoran P; Ortonne JP; Baron V; Ballotti R; Tartare-Deckert S
J Invest Dermatol; 2007 Feb; 127(2):400-10. PubMed ID: 16960555
[TBL] [Abstract][Full Text] [Related]
12. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
Hu R; Aplin AE
Pigment Cell Melanoma Res; 2010 Apr; 23(2):201-9. PubMed ID: 20067552
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 is required for melanoma cell resistance to anoikis.
Boisvert-Adamo K; Longmate W; Abel EV; Aplin AE
Mol Cancer Res; 2009 Apr; 7(4):549-56. PubMed ID: 19372583
[TBL] [Abstract][Full Text] [Related]
14. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
15. FOXQ1 controls the induced differentiation of melanocytic cells.
Bagati A; Bianchi-Smiraglia A; Moparthy S; Kolesnikova K; Fink EE; Kolesnikova M; Roll MV; Jowdy P; Wolff DW; Polechetti A; Yun DH; Lipchick BC; Paul LM; Wrazen B; Moparthy K; Mudambi S; Morozevich GE; Georgieva SG; Wang J; Shafirstein G; Liu S; Kandel ES; Berman AE; Box NF; Paragh G; Nikiforov MA
Cell Death Differ; 2018 Jun; 25(6):1040-1049. PubMed ID: 29463842
[TBL] [Abstract][Full Text] [Related]
16. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
17. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C
J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597
[TBL] [Abstract][Full Text] [Related]
18. FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.
Li K; Guo Q; Yang J; Chen H; Hu K; Zhao J; Zheng S; Pang X; Zhou S; Dang Y; Li L
Oncotarget; 2017 Jan; 8(3):5048-5056. PubMed ID: 27926503
[TBL] [Abstract][Full Text] [Related]
19. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.
Weiss MB; Abel EV; Mayberry MM; Basile KJ; Berger AC; Aplin AE
Cancer Res; 2012 Dec; 72(24):6382-92. PubMed ID: 23222305
[TBL] [Abstract][Full Text] [Related]
20. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Smit MA; Maddalo G; Greig K; Raaijmakers LM; Possik PA; van Breukelen B; Cappadona S; Heck AJ; Altelaar AF; Peeper DS
Mol Syst Biol; 2014 Dec; 10(12):772. PubMed ID: 25538140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]